Orchestra BioMed Holdings (OBIO) Revenue (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Revenue of $110000.0 for Q1 2026, down 87.33% year-over-year from $868000.0 in Q1 2025, and down 99.64% quarter-over-quarter from $30.9 million in Q4 2025.
Orchestra BioMed Holdings (OBIO) Revenue (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Revenue for 5 consecutive years, with $110000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue fell 87.33% year-over-year to $110000.0; the TTM figure through Mar 2026 stood at $32.7 million (up 1033.89% YoY), while the FY2025 annual figure was $33.5 million, up 1169.22% from the prior year.
- Revenue declined to $110000.0 in Q1 2026 per OBIO's latest filing, from $30.9 million in the prior quarter.
- Across five years, Revenue topped out at $30.9 million in Q4 2025 and bottomed at $110000.0 in Q1 2026.
- Historically, Revenue has averaged $2.5 million across 5 years, with a median of $861000.0 in 2025.
- Annual changes were most pronounced in 2025 — Revenue jumped 12120.16% — and 2026, when it sank 87.33%.
- Orchestra BioMed Holdings' Revenue stood at $1.1 million in 2022, then sank by 76.25% to $262000.0 in 2023, then slipped by 3.44% to $253000.0 in 2024, then surged by 12120.16% to $30.9 million in 2025, then tumbled by 99.64% to $110000.0 in 2026.
- Business Quant data shows OBIO's Revenue at $110000.0 in Q1 2026, $30.9 million in Q4 2025, and $861000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Orchestra BioMed Holdings | 265.06 Mn | 80.63 Mn | 63,000.00 | 88,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 88,000.00 |
| Mar 31, 2026 | 110,000.00 |
| Dec 31, 2025 | 30.92 Mn |
| Sep 30, 2025 | 861,000.00 |
| Jun 30, 2025 | 836,000.00 |
| Mar 31, 2025 | 868,000.00 |
| Dec 31, 2024 | 253,000.00 |
| Sep 30, 2024 | 987,000.00 |
| Jun 30, 2024 | 778,000.00 |
| Mar 31, 2024 | 620,000.00 |
| Dec 31, 2023 | 262,000.00 |
| Sep 30, 2023 | 419,000.00 |
| Jun 30, 2023 | 915,000.00 |
| Mar 31, 2023 | 1.16 Mn |
| Dec 31, 2022 | 1.10 Mn |
| Sep 30, 2022 | 1.16 Mn |
| Jun 30, 2022 | 401,000.00 |
| Mar 31, 2022 | 866,000.00 |